

January 4, 2016



Navidea Biopharmaceuticals to Present at Biotech Showcase 2016

DUBLIN, Ohio--(BUSINESS WIRE)-- Navidea Biopharmaceuticals, Inc. (NYSE MKT: NAVB) announced that Rick Gonzalez, President and Chief Executive Officer, will present at the Biotech Showcase 2016, taking place in San Francisco, CA, on Tuesday, January 12th at 2:30 PM PT (5:30 PM ET) at the Parc 55 San Francisco – Union Square.

A live webcast of Mr. Gonzalez's Biotech Showcase presentation can be accessed at the following URL: <http://edge.media-server.com/m/p/6j593adk>. An archived version of the webcast will be available two hours following the presentation and can be accessed within the Investors' section of the Navidea website at www.navidea.com.

About Navidea

Navidea Biopharmaceuticals, Inc. (NYSE MKT: NAVB) is a biopharmaceutical company focused on the development and commercialization of precision immunodiagnostic agents and immunotherapeutics. Navidea is developing multiple precision-targeted products and platforms including Manocept™ and NAV4694 to help identify the sites and pathways of undetected disease and enable better diagnostic accuracy, clinical decision-making, targeted treatment and, ultimately, patient care. Lymphoseek® (technetium Tc 99m tilmanocept) injection, Navidea's first commercial product from the Manocept platform, was approved by the FDA in March 2013 and in Europe in November 2014. Navidea's strategy is to deliver superior growth and shareholder return by bringing to market novel products and advancing the Company's pipeline through global partnering and commercialization efforts. For more information, please visit www.navidea.com.

View source version on businesswire.com:

<http://www.businesswire.com/news/home/20160104005760/en/>

Navidea Biopharmaceuticals

Investors

Tom Baker, 617-532-0624

tbaker@navidea.com

or

Media

Sharon Correia, 978-655-2686

Associate Director, Corporate Communications

or

David Shull or Chris Hippolyte, 858-717-2310

david.schull@russopartnersllc.com

Chris.hippolyte@russopartnersllc.com

Source: Navidea Biopharmaceuticals, Inc.